Aldagen and Innovative Micro Technology (IMT) formed an alliance to co-develop and commercialize a version of IMT’s Rare Cell Purification System customized specifically for clinical cell therapies. This system, called the Aldesorter™, will be used with Aldagen’s Aldesort® product to isolate unique stem cell populations to treat chronic heart failure, peripheral vascular disease, leukemias, genetic enzyme deficiencies, and other diseases.
Aldagen’s Aldesort product is a set of reagents that can be used with currently available cell-sorting systems to isolate a highly potent population of stem and progenitor cells from human bone marrow, peripheral blood, and cord blood. Aldesort product’s chemistry allows the isolation of stem and progenitor cells, based on the elevated expression of an intracellular enzyme, aldehyde dehydrogenase.
The first Aldesorter is scheduled for completion in early 2007, with clinical trials planned to begin in late 2007.